(Circulation. 2000;101:2040.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Type II Diabetes Abrogates Sex Differences in Endothelial Function in Premenopausal Women
From the Department of Medicine, Indiana University School of Medicine (H.O.S., G.P., J.C., K.C., A.H., G.H., A.D.B.), and the Richard L. Roudebush Veterans Affairs Medical Center (G.H., A.D.B.), Indianapolis, Ind.
Correspondence to Alain D. Baron, MD, Indiana University School of Medicine, 541 N Clinical Dr, CL 459, Indianapolis, IN 46202-5111. E-mail abaron{at}iupui.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Obesity is a more potent cardiovascular risk factor (CVRF) in men than in women. Because traditional CVRFs cannot fully account for this sex difference, we tested the hypothesis that compared with men, women exhibit more robust endothelial function independent of obesity and that this sex difference is abrogated by diabetes.
Methods and Results—We studied leg blood flow (LBF) responses to graded intrafemoral artery infusions of the endothelium-dependent vasodilator methacholine chloride (Mch) and the endothelium-independent vasodilator sodium nitroprusside (SNP) in groups of lean, obese (OB), and type II diabetic (DM) premenopausal women and age- and body mass index–matched men. LBF response to intrafemoral administration of L-NMMA, an inhibitor of nitric oxide synthase, was also assessed in normal men and women. Maximum LBF increments in response to Mch were 347±57% versus 231±22% in lean women versus men (P<0.05) and 203±25% versus 111±17% in OB women versus men (P<0.01), respectively. In DM, maximum LBF increments in response to Mch were 104±24% and 138±33% in women and men, respectively, (P=NS). LBF decrements in response to L-NMMA were 34.9±4.1% and 17.1±4.2% in women and men, respectively (P<0.01). The response to SNP was not different between sexes and groups.
Conclusions—Premenopausal nondiabetic women exhibit more robust endothelium-dependent vasodilation owing to higher rates of nitric oxide release than men. Given the protective vascular action of nitric oxide, this difference may partially explain the lower incidence of macrovascular disease in women. In premenopausal women, DM causes impairment of endothelial function beyond that observed with obesity alone and leads to endothelial dysfunction similar to that observed in DM men. These findings may help explain the similar rates of coronary artery disease and mortality in diabetic men and women.
Key Words: endothelium • obesity • diabetes mellitus • sex
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Obesity is considered an independent risk factor for macrovascular disease.1 2 Despite a higher prevalence of obesity in women,3 the incidence of macrovascular disease is significantly lower in premenopausal women than men even when matched for traditional cardiovascular risk factors (CVRFs). Obesity (particularly when centrally distributed) is characteristically accompanied by insulin resistance, which is associated with a cluster of CVRFs.4 Adding to the list of CVRFs, we recently reported impaired endothelium-dependent vasodilation (EDV) in healthy obese insulin-resistant subjects.5 On closer analysis of our data, we noted possible sex differences in EDV. Given the central role of the endothelium to modulate vascular tone, lipid peroxidation, smooth muscle proliferation and migration, and monocyte adhesion,6 sex differences in endothelial function could partially account for the sex differences in cardiovascular events previously noted. Therefore, we hypothesized that compared with men, women exhibit higher rates of basal nitric oxide (NO)-dependent blood flow and more robust EDV independent of obesity. Furthermore, because the mortality from macrovascular disease is 3- to 5-fold higher in type II diabetic women7 8 than in nondiabetic women and reaches coronary event rates similar to those of diabetic men, we reasoned that if endothelial dysfunction is in fact an important CVRF, both diabetic men and women would exhibit similar degrees of endothelial dysfunction. In other words, we hypothesized that type II diabetes abrogates differences in endothelial function between sexes.
We studied leg blood flow (LBF) changes in response to graded intrafemoral artery infusions of the endothelium-dependent vasodilator methacholine chloride (Mch) and the endothelium-independent vasodilator sodium nitroprusside (SNP) in groups of lean, obese (OB), and OB type II diabetic (DM) men and women. Furthermore, to assess NO-dependent vascular tone, we measured LBF changes in response to the inhibitor of NO synthase NG-monomethyl-L-arginine (L-NMMA).
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Population
Study subjects were healthy, with normal cuff blood pressure. DM subjects were withdrawn from oral antidiabetic drugs
4 weeks before
studies. Long-acting and intermediate-acting insulin was stopped 1 week
before the study, and regular insulin was withheld for a minimum of 24
hours before the study. Obesity was defined as body mass index (weight
[kg])/(height [m2]) 26 in men and 28 in
women. Studies were approved by the Indiana University Institutional
Review Board, and all volunteers gave informed consent.
Protocol
All studies were done after an overnight fast. A 6F sheath
(Cordis Corp) was placed into the right femoral vein to allow the
insertion of a custom-designed 5F double-lumen thermodilution catheter
(Baxter Scientific, Edwards Division) to measure LBF. The right femoral
artery was cannulated with a 5.5F double-lumen catheter to allow
simultaneous infusion of substances and invasive blood
pressure monitoring via a vital signs monitor (Spacelabs).
All hemodynamic measurements were obtained with the
subjects in the supine position in a quiet temperature-controlled room.
Baseline LBF and mean arterial pressure measurements were
obtained after 30 minutes of rest after the insertion of the
catheters. Rates of LBF were obtained with the thermodilution technique
and calculated by a cardiac output computer (model 9520A, American
Edwards Laboratories). During baseline, 24 LBF measurements were
obtained at 
30-second intervals. During drug infusion, LBF
measurements were begun 2 minutes after the onset of each dose, and 10
measurements were taken for each dose. Invasively determined MAP was
recorded with every other LBF determination.
Graded intrafemoral artery infusions of Mch or SNP (Roche Laboratories) were administered at sequential doses of 2.5, 5.0, 7.5, 10.0, 12.5, and 15.0 µg/min (0.1 to 0.6 mL/min) or 1.75, 3.5, and 7.0 µg/min (0.25 to 1.0 mL/min) to assess stimulated endothelium-dependent or endothelium-independent vasodilation, respectively. Basal NO-dependent vasodilation was assessed by an intrafemoral artery infusion of L-NMMA (Clinalfa), an inhibitor of NO synthase, at a dose of 16 mg/min for 15 minutes (2.0 mL/min). The responses to Mch, SNP, and L-NMMA were studied in separate groups.
Statistical Analysis
Comparison between groups was performed by factorial or
repeated-measures ANOVA. When significant differences between groups
were found by ANOVA, this was followed by post hoc testing with
Fisher’s protected least significant difference test. Because basal
LBF differed significantly between groups, changes in blood flow are
expressed as percent change (%
) to adjust for differences at
baseline. Univariate regression analysis between
the maximum changes in LBF (% LBF) in response to Mch and other
variables known to modulate this response was performed after
transformation of % LBF to its square root. Statistical
significance was accepted at a level of P<0.05. All results
are shown as the mean±SEM.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mch Study: Endothelium-Dependent Vasodilation
Metabolic and baseline hemodynamic characteristics of the study group are shown in Table 1
. As expected, the groups
exhibited differences in these characteristics due to the presence of
obesity and/or type II diabetes.
|
In the men, the increments in LBF (Figure 1A) were significantly reduced in the OB
and DM subjects. Lean subjects exhibited a nearly 2-fold higher rise in
LBF than both OB and DM subjects (P<0.01). Maximum LBF
increments were 231±22%, 111±17%, and 138±33% in lean, OB, and
DM, respectively (P<0.05 lean versus OB and DM). In the
women, the increase in LBF (Figure 1B) was significantly reduced
in OB and DM. However, although OB women had a significantly smaller
response than the lean women, they still exhibited nearly twice the
rise in LBF compared with DM (P<0.05). Maximum LBF
increments were 347±57%, 203±25%, and 104±24% in lean, OB, and
DM, respectively (P<0.01 between all groups). These data
indicate that obesity and type II diabetes are associated with impaired
endothelial function. Matching OB and DM women for
waist-to-hip ratio (data not shown) did not attenuate the difference in
LBF responses.
|
To further demonstrate that sex differences exist in the vascular
response to Mch, we compared the LBF increments in response to Mch
between sexes according to their groups (lean, OB, and DM). Lean women
exhibited 40% more pronounced increases in LBF (Figure 2A) than lean men, and the maximal LBF
response to Mch was 347±57% versus 231±22% in female and male
subjects, respectively (P<0.05). OB women exhibited nearly
twice the LBF increments in response to Mch than the OB men (Figure 2B), and the maximal LBF response to Mch was 203±25% versus
111±17% in female and male subjects, respectively
(P<0.01). Matching OB men and women for absolute body fat
mass (data not shown) did not alter the results. In contrast to lean
and OB women, DM women exhibited responses to Mch similar to those of
DM men (Figure 2C), and maximal increments in LBF in response to
Mch were 138±33% and 104±24% (P=NS) in men and women,
respectively.
|
These data indicate that EDV is modulated by sex and is more robust in nondiabetic premenopausal women than in nondiabetic men and that this sex difference is abrogated by diabetes.
Univariate analysis between maximum response to Mch
and other factors known to determine endothelial
function, such as indices of body fat content, blood pressure, age, and
cholesterol, revealed that body mass index, percent body
fat content, hip and waist circumference, absolute body fat mass, and
free fatty acid (FFA) levels achieved statistical significance (Table 2). Exclusion of the diabetic subjects
did not change the results of these analyses. Using
multivariate or stepwise regression analysis
did not alter this finding, indicating that body fat content, body fat
distribution, and basal serum FFAs appear to be the most important
determinants of endothelial dysfunction.
|
L-NMMA Study: Basal NO-Dependent Vasodilation
Metabolic and baseline hemodynamic
characteristics of the study group are shown in Table 3.
|
In response to intrafemoral L-NMMA, LBF decreased to 0.169±0.020 and
0.187±0.025 L/min in the male and female groups, respectively
(P<0.05 versus basal, both groups). The fall in LBF in
response to L-NMMA (Figure 3) was
17.1±4.2% and 34.9±4.1% in the male and female groups, respectively
(P<0.01), indicating that women exhibit higher rates of
basal NO production even in the face of higher body fat content
(Table 3
).
|
SNP Study: Endothelium-Independent
Vasodilation
Metabolic and baseline hemodynamic
characteristics of the study group are shown in Table 4. As expected, the groups exhibited
differences in these characteristics due to the presence of obesity
and/or type II diabetes.
|
In both men and women, the LBF response to SNP was comparable between
lean, OB, and DM subjects (Figure 4A and 4B). No differences were found in the LBF response to SNP between men
and women. These results indicate that
endothelium-independent vasodilation is not modulated
by sex or impaired by obesity or type II diabetes.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Obesity is an independent risk factor for macrovascular disease across sexes.1 9 10 However, despite higher incidence of obesity in premenopausal women, rates of macrovascular disease are lower in premenopausal women than in men. Interestingly, this sex difference, which normally vanishes after menopause,11 is rapidly lost in premenopausal DM patients, with cardiovascular disease reaching 2- to 5-fold higher rates than in nondiabetic women.8 In fact, women with type II diabetes, compared with age-matched nondiabetic women, exhibit 5-fold7 to 8-fold12 higher rates of death related to coronary artery disease, with event rates nearly identical to those observed in type II diabetic men. Traditional CVRFs cannot completely account for these sex differences in cardiovascular mortality.13
The results of our study demonstrate that (1) NO-dependent basal vascular tone and EDV is enhanced in nondiabetic premenopausal women compared with men; (2) obesity/insulin resistance is associated with blunting of EDV in both sexes, and this effect is markedly more pronounced in men; (3) although type II diabetes in men does not further reduce EDV beyond that observed with obesity, diabetes in obese women causes impairment of EDV above and beyond that observed with obesity alone; and (4) diabetes was associated with similar endothelial dysfunction in women and men. Together, these results suggest that premenopausal women exhibit higher rates of NO production than men independent of obesity and that this sex difference is abrogated by type II diabetes. Moreover, obesity appears to have a more potent effect to diminish endothelial function in men than in women.
The increased effect of Mch in nondiabetic women could be due to (1) increased NO production/release, (2) increased NO action at the level of the vascular smooth muscle in the women, or (3) decreased NO action at the level of the vascular smooth muscle in the men. Differences in NO action between sexes are highly unlikely, because the effect of graded intrafemoral artery infusions of the exogenous NO donor SNP did not differ between sexes, indicating no differences in vascular smooth muscle cell responses to NO between sexes. Thus, our data indicate that the increased vasodilator response to Mch in nondiabetic premenopausal women is due, at least in large part, to increased production/release of NO.
Because vascular responses to muscarinergic agonists like Mch or acetylcholine are not mediated exclusively by the release of NO,14 other vasodilating factors may mediate some of the vascular response. One of these, the endothelium-dependent hyperpolarizing factor, has been shown to contribute more to EDV in female than male rat mesenteric arteries.15 Therefore, differences in endothelium-dependent hyperpolarizing factor release or action could theoretically also partially explain the sex differences in EDV.
We also examined basal NO-dependent vascular tone by measuring LBF
response to intrafemoral artery administration of L-NMMA, an
inhibitor of NO. Nondiabetic women, compared with
nondiabetic men, exhibited 2-fold greater LBF decrements in response
to intrafemoral artery infusions of L-NMMA. These results indicate that
women exhibit higher rates of basal NO production than men, as
suggested by Forte et al,16 who measured whole-body NO
production. This difference in NO-dependent vascular tone is
all the more significant because both sex groups were well matched for
factors known to impair EDV, such as age,17 blood
pressure,18 and FFA19 and
cholesterol20 levels.
It is important to emphasize that, even when matched for body mass index, women tended to have significantly higher body fat content than men, which is consistent with other reports.21 22 23 Because obesity/insulin resistance has been shown by us5 and others24 to be associated with impaired EDV, one would have predicted reduced LBF responses to both L-NMMA and Mch in women. Further studies will be necessary to determine whether fat distribution could account for these differences, because dual x-ray absorptiometry as used in this study does not quantify intra-abdominal adiposity. Nevertheless, our data support the notion that sex has a major modulating effect on endothelial function independent of obesity.
The precise mechanism(s) for the enhanced NO-dependent endothelial vasodilation in premenopausal nondiabetic women is unknown. Obviously, sex differences in sex hormones may be one explanation for the differences in NO production/release. In endothelial cell cultures, estrogen, the predominant female sex hormone, has been shown to stimulate NO synthesis.25 Vascular strips from female rats were found to release more NO in response to acetylcholine than vascular strips from male rats.26 27 In humans, estrogen replacement restored the blunted blood flow response to acetylcholine in women who underwent ovariectomy28 and in postmenopausal women.29 These data suggest that estrogen may directly stimulate NO production/release in women. Conversely, the predominant male sex hormone testosterone (or other androgens) may cause decreased NO production/release, as suggested by Herman and colleagues.30 The independent contributions of estrogens and androgens to the control of endothelial function in normal and pathophysiological states remains to be fully elucidated.
In addition, differences in insulin sensitivity between men and women may also account for higher rates of NO production/release in women. Several reports have demonstrated that women display nearly 50% higher insulin sensitivity than men when matched for age and body mass index,22 23 suggesting that sex modulates the association between body fat content and insulin sensitivity. We5 and others24 have shown that insulin sensitivity correlates positively with the magnitude of the blood flow responses to Mch and L-NMMA. Therefore, the greater endothelial dysfunction observed in men may be secondary to the more reduced insulin sensitivity in men versus women.
The mechanism(s) by which obesity impairs EDV is not well understood. Obesity is associated with elevated FFA,31 32 and we have previously shown19 that elevation of FFA in lean insulin-sensitive subjects caused blunting of EDV. Furthermore, elevation of FFA in vitro33 34 decreases NO production in endothelial cells. We found that FFA levels and the maximum response to Mch were significantly and inversely related. Taken together, our findings suggest that elevation of FFA levels in OB and OB DM subjects may be causally related to the observed endothelial dysfunction.
It is important to note that the presence of diabetes caused a further impairment of EDV in women but not in men. This suggests that obesity alone caused a maximal reduction in EDV in men and a submaximal effect in women. The slightly higher LDL cholesterol levels in the diabetic women may account for a small proportion (10% to 20%) of the difference in the LBF response to Mch. At the very least, our data further suggest that obesity is sufficient to cause endothelial dysfunction associated with decreased NO release in men, whereas superimposed hyperglycemia is necessary to produce similar degrees of endothelial impairment in woman.
Finally, it is important to consider the clinical implications of our data. Assuming that endothelial dysfunction is important in the development of macrovascular disease,35 it follows that control of hyperglycemia would be expected to have only a modest effect to reduce macrovascular disease in men, because this intervention would have limited effects to improve insulin sensitivity (reverse insulin resistance) and thus would not benefit endothelial function. In contradistinction, therapeutic interventions to control hyperglycemia would be expected to have dramatic effects in premenopausal women, because this maneuver would be expected to greatly ameliorate endothelial function. Conversely, maneuvers directed at reducing both obesity/insulin resistance (weight loss, exercise, insulin-sensitizing drugs) and hyperglycemia would be expected to greatly reduce macrovascular disease in both men and women. In this context, it is interesting that the results of the UK Prospective Diabetes Study36 showed only marginal effects of glycemic control alone (without amelioration of insulin resistance) on macrovascular disease. Unfortunately, an analysis examining sex differences in these outcomes has yet to be presented.
In summary, obesity/insulin resistance is associated with impaired endothelial function (reduced NO release) in both sexes, but this effect is remarkably more pronounced in men. Given the vasoprotective properties of endothelium-derived NO, this relative preservation of endothelial function may explain, at least in part, the decreased incidence of hypertension and cardiovascular disease in nondiabetic premenopausal women. Importantly, the development of severe endothelial dysfunction in women with type II diabetes could explain the epidemiological finding that type II diabetic women and men display similar elevated cardiovascular risk.
|
Acknowledgments |
|---|
This work was supported by grants DK-42469, MO1-RR750-19, and DK-20542 from the National Institutes of Health and a Veterans Affairs Merit Review Award. The authors wish to thank Joyce Ballard for her expert and invaluable help in preparing the manuscript and Keryl Holloway for her technical assistance.
Received August 24, 1999; revision received November 19, 1999; accepted December 10, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P. Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation. 1996;93:1372–1379.
2.
Seidell JC, Verschuren WM, van Leer EM, Kromhout D.
Overweight, underweight, and mortality: a prospective study of 48,287
men and women. Arch Intern Med. 1996;156:958–963.
3.
From the Centers for Disease Control and Prevention.
Update: prevalence of overweight among children, adolescents, and
adults—United States, 1988–1994. JAMA. 1997;277:1111.
4. Reaven GM. Syndrome X: 6 years later. J Intern Med. 1994;236:13–22.
5. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601–2610.[Medline] [Order article via Infotrieve]
6. Lloyd-Jones DM, Bloch KD. The vascular biology of nitric oxide and its role in atherogenesis. Annu Rev Med. 1996;47:365–375.[Medline] [Order article via Infotrieve]
7.
Pan WH, Cedres LB, Liu K, Dyer A, Schoenberger JA,
Shekelle RB, Stamler R, Smith D, Collette P, Stamler J. Relationship of
clinical diabetes and asymptomatic hyperglycemia to risk of
coronary heart disease mortality in men and women.
Am J Epidemiol. 1986;123:504–516.
8.
Kannel WB, McGee DL. Diabetes and
cardiovascular disease: the Framingham study.
JAMA. 1979;241:2035–2038.
9.
Hubert HB, Feinleib M, McNamara PM, Castelli WP.
Obesity as an independent risk factor for
cardiovascular disease: a 26 year follow up of
participants in the Framingham Heart Study. Circulation. 1983;67:968–977.
10.
Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter
DJ, Hankinson SE, Hennekens CH, Speizer F. Body weight and mortality
among women. N Engl J Med. 1995;333:677–685.
11. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med. 1976;85:447–452.
12. Jarrett RJ, McCartney P, Keen H. The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia. 1982;22:79–84.[Medline] [Order article via Infotrieve]
13. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463–524.[Medline] [Order article via Infotrieve]
14. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest. 1997;100:2793–2799.[Medline] [Order article via Infotrieve]
15. McCulloch AI, Randall MD. Sex differences in the relative contributions of nitric oxide and EDHF to agonist-stimulated endothelium-dependent relaxations in the rat isolated mesenteric arterial bed. Br J Pharmacol. 1998;123:1700–1706.[Medline] [Order article via Infotrieve]
16.
Forte P, Kneale BJ, Milne E, Chowienczyk PJ, Johnston
A, Benjamin N, Ritter JM. Evidence for a difference in nitric oxide
biosynthesis between healthy women and men. Hypertension. 1998;32:730–734.
17.
Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging
progressively impairs endothelium-dependent
vasodilation in forearm resistance vessels of humans.
Hypertension. 1996;27:849–853.
18. Panza JA, Quyyumi A, Brush JE, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22–27.[Abstract]
19. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 1997;100:1230–1239.[Medline] [Order article via Infotrieve]
20.
Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA.
The role of nitric oxide in endothelium-dependent
vasodilation of hypercholesterolemic patients.
Circulation. 1993;88:2541–2547.
21. Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr. 1991;65:105–114.[Medline] [Order article via Infotrieve]
22. Nuutila P, Knuuti MJ, Maki M, Laine H, Ruotsalainen U, Teras M, Haaparanta M, Solin O, Yki-Jarvinen H. Gender and insulin sensitivity in the heart and in skeletal muscles: studies using positron emission tomography. Diabetes. 1995;44:31–36.[Abstract]
23. Yki-Jarvinen H. Sex and insulin sensitivity. Metabolism. 1984;33:1011–1015.[Medline] [Order article via Infotrieve]
24.
Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell
JMC. Endothelial nitric oxide production and
insulin sensitivity: a physiological link with
implications for pathogenesis of cardiovascular
disease. Circulation. 1996;93:1331–1333.
25.
Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS,
German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide
synthase activity in fetal pulmonary artery
endothelium. Am J Physiol. 1997;273:L119–L126.
26.
Kauser K, Rubanyi GM. Gender difference in
bioassayable endothelium-derived nitric oxide from
isolated rat aortae. Am J Physiol. 1994;267:H2311–H2317.
27. Huang A, Sun D, Koller A, Kaley G. Gender difference in flow-induced dilation and regulation of shear stress: role of estrogen and nitric oxide. Am J Physiol. 1998;275:R1571–R1577.
28.
Pinto S, Virdis A, Ghiadoni L, Bernini G, Lombardo M,
Petraglia F, Genazzani AR, Taddei S, Salvetti A. Endogenous
estrogen and acetylcholine-induced vasodilation in normotensive women.
Hypertension. 1997;29:268–273.
29. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. Short-term estrogen augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilation in postmenopausal women. J Cardiovasc Pharmacol. 1997;30:481–488.[Medline] [Order article via Infotrieve]
30.
Herman SM, Robinson JTC, McCredie RJ, Adams MR, Boyer
MJ. Androgen deprivation is associated with enhanced
endothelium dependent-vasodilation in adult men.
Arterioscler Thromb Vasc Biol. 1997;17:2004–2009.
31. Herranz L, Zapata A, Grande C, Megia A, Pallardo LF. Body fat distribution, insulin mediated suppression of non-esterified fatty acids and plasma triglycerides in obese subjects. Horm Metab Res. 1998;30:141–145.[Medline] [Order article via Infotrieve]
32. Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci. 1998;3:D169–D175.
33. Gupta MP, Steinberg H, Baron A, Hart CM. Fatty acids impair nitric oxide production in cultured endothelial cells. J Invest Med. 1998;46:288A. Abstract.
34.
Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend
TL, Egan BM. Oleic acid inhibits endothelial nitric
oxide synthase by a protein kinase C-independent mechanism.
Hypertension. 1995;26:764–770.
35.
Cannon RO III. Role of nitric oxide in
cardiovascular disease: focus on the
endothelium. Clin Chem. 1998;44:1809–1819.
36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  A. S. Shah, L. M. Dolan, T. R. Kimball, Z. Gao, P. R. Khoury, S. R. Daniels, and E. M. Urbina Influence of Duration of Diabetes, Glycemic Control, and Traditional Cardiovascular Risk Factors on Early Atherosclerotic Vascular Changes in Adolescents and Young Adults with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3740 - 3745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sixt, S. Beer, M. Bluher, N. Korff, T. Peschel, M. Sonnabend, D. Teupser, J. Thiery, V. Adams, G. Schuler, et al. Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease Eur. Heart J., September 30, 2009; (2009) ehp398v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goel, D. Thor, L. Anderson, and R. Rahimian Sexual dimorphism in rabbit aortic endothelial function under acute hyperglycemic conditions and gender-specific responses to acute 17{beta}-estradiol Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2411 - H2420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Dale, T. I. Nilsen, L. Vatten, K. Midthjell, and R. Wiseth Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74 914 individuals in the HUNT 1 Study Eur. Heart J., December 1, 2007; 28(23): 2924 - 2929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goel, Y. Zhang, L. Anderson, and R. Rahimian Gender difference in rat aorta vasodilation after acute exposure to high glucose: Involvement of protein kinase C {beta} and superoxide but not of Rho Kinase Cardiovasc Res, November 1, 2007; 76(2): 351 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gkaliagkousi, A. Shah, and A. Ferro Review: Pharmacological and non-pharmacological treatment of endothelial dysfunction: relevance to diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2007; 7(1): 5 - 10. [Abstract] [PDF]
|
|
|
|
 |
|
 H.-F. Chen, C.-A. Ho, and C.-Y. Li Age and Sex May Significantly Interact With Diabetes on the Risks of Lower-Extremity Amputation and Peripheral Revascularization Procedures: Evidence from a cohort of a half-million diabetic patients. Diabetes Care, November 1, 2006; 29(11): 2409 - 2414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Guazzi, S. Belletti, E. Bianco, L. Lenatti, and M. D. Guazzi Endothelial dysfunction and exercise performance in lone atrial fibrillation or associated with hypertension or diabetes: different results with cardioversion Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H921 - H928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Wexler, R. W. Grant, J. B. Meigs, D. M. Nathan, and E. Cagliero Sex Disparities in Treatment of Cardiac Risk Factors in Patients With Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rossi, E. Cioni, A. Nuzzo, G. Origliani, and M. G. Modena Endothelial-Dependent Vasodilation and Incidence of Type 2 Diabetes in a Population of Healthy Postmenopausal Women Diabetes Care, March 1, 2005; 28(3): 702 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Natarajan, Y. Liao, D. Sinha, G. Cao, D. L. McGee, and S. R. Lipsitz Sex Differences in the Effect of Diabetes Duration on Coronary Heart Disease Mortality Arch Intern Med, February 28, 2005; 165(4): 430 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Juutilainen, S. Kortelainen, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Gender Difference in the Impact of Type 2 Diabetes on Coronary Heart Disease Risk Diabetes Care, December 1, 2004; 27(12): 2898 - 2904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Barrett-Connor, E.-G. V. Giardina, A. K. Gitt, U. Gudat, H. O. Steinberg, and D. Tschoepe Women and Heart Disease: The Role of Diabetes and Hyperglycemia Arch Intern Med, May 10, 2004; 164(9): 934 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Hurst and R. W. Lee Increased Incidence of Coronary Atherosclerosis in Type 2 Diabetes Mellitus: Mechanisms and Management Ann Intern Med, November 18, 2003; 139(10): 824 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Graham, W. A. Ghali, P. D. Faris, P. D. Galbraith, C. M. Norris, and M. L. Knudtson Sex Differences in the Prognostic Importance of Diabetes in Patients With Ischemic Heart Disease Undergoing Coronary Angiography Diabetes Care, November 1, 2003; 26(11): 3142 - 3147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Natarajan, Y. Liao, G. Cao, S. R. Lipsitz, and D. L. McGee Sex Differences in Risk for Coronary Heart Disease Mortality Associated With Diabetes and Established Coronary Heart Disease Arch Intern Med, July 28, 2003; 163(14): 1735 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Sanz, N. Fernandez, L. Monge, B. Climent, G. Dieguez, and A. L. Garcia-Villalon Relaxation by urocortin of rat renal arteries: effects of diabetes in males and females Cardiovasc Res, June 1, 2003; 58(3): 706 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Clouse, P. J. Lustman, K. E. Freedland, L. S. Griffith, J. B. McGill, and R. M. Carney Depression and Coronary Heart Disease in Women With Diabetes Psychosom Med, May 1, 2003; 65(3): 376 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Paradisi, H. O. Steinberg, M. K. Shepard, G. Hook, and A. D. Baron Troglitazone Therapy Improves Endothelial Function to Near Normal Levels in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 576 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Olive, J. M. Slade, G. A. Dudley, and K. K. McCully Blood flow and muscle fatigue in SCI individuals during electrical stimulation J Appl Physiol, February 1, 2003; 94(2): 701 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Mather, B. Mirzamohammadi, A. Lteif, H. O. Steinberg, and A. D. Baron Endothelin Contributes to Basal Vascular Tone and Endothelial Dysfunction in Human Obesity and Type 2 Diabetes Diabetes, December 1, 2002; 51(12): 3517 - 3523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Paradisi, A. Biaggi, S. Ferrazzani, S. De Carolis, and A. Caruso Abnormal Carbohydrate Metabolism During Pregnancy : Association with endothelial dysfunction Diabetes Care, March 1, 2002; 25(3): 560 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Marra, P. Cotroneo, D. Pitocco, A. Manto, M. A.S. Di Leo, V. Ruotolo, S. Caputo, B. Giardina, G. Ghirlanda, and S. A. Santini Early Increase of Oxidative Stress and Reduced Antioxidant Defenses in Patients With Uncomplicated Type 1 Diabetes: A case for gender difference Diabetes Care, February 1, 2002; 25(2): 370 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Arad, D. Newstein, F. Cadet, M. Roth, and A. D. Guerci Association of Multiple Risk Factors and Insulin Resistance With Increased Prevalence of Asymptomatic Coronary Artery Disease by an Electron-Beam Computed Tomographic Study Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 2051 - 2058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh, M. H. Kang, D. K. Jin, S.-K. Lee, J. Y. Ahn, H. Y. Hwang, S. H. Yang, D. S. Kim, T. H. Ahn, and E. K. Shin Vascular effects of estrogen in type II diabetic postmenopausal women J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1409 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. B. Hu, M. J. Stampfer, C. G. Solomon, S. Liu, W. C. Willett, F. E. Speizer, D. M. Nathan, and J. E. Manson The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women: 20 Years of Follow-up Arch Intern Med, July 23, 2001; 161(14): 1717 - 1723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Al Suwaidi, S. T. Higano, D. R. Holmes Jr., R. Lennon, and A. Lerman Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1523 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Mather, S. Verma, and T. J. Anderson Improved endothelial function with metformin in type 2 diabetes mellitus J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1344 - 1350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Paradisi, H. O. Steinberg, A. Hempfling, J. Cronin, G. Hook, M. K. Shepard, and A. D. Baron Polycystic Ovary Syndrome Is Associated With Endothelial Dysfunction Circulation, March 13, 2001; 103(10): 1410 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M Lefer, R. Scalia, and D. J Lefer Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease Cardiovasc Res, February 1, 2001; 49(2): 281 - 287. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||